Equities analysts predict that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will post sales of $91.20 million for the current quarter, according to Zacks. Five analysts have made estimates for AMAG Pharmaceuticals’ earnings. The lowest sales estimate is $83.00 million and the highest is $96.38 million. AMAG Pharmaceuticals reported sales of $146.25 million in the same quarter last year, which indicates a negative year over year growth rate of 37.6%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that AMAG Pharmaceuticals will report full year sales of $367.83 million for the current year, with estimates ranging from $340.70 million to $384.40 million. For the next financial year, analysts forecast that the business will post sales of $351.96 million, with estimates ranging from $283.00 million to $419.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($3.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($2.77). AMAG Pharmaceuticals had a negative net margin of 30.90% and a negative return on equity of 26.33%. The company had revenue of $75.80 million for the quarter, compared to the consensus estimate of $90.13 million. During the same quarter in the prior year, the company earned ($1.59) earnings per share. The company’s quarterly revenue was down 35.4% on a year-over-year basis.
Shares of AMAG stock traded up $0.04 during trading on Friday, hitting $9.27. The company had a trading volume of 581,400 shares, compared to its average volume of 773,349. The company has a quick ratio of 2.13, a current ratio of 2.30 and a debt-to-equity ratio of 0.44. The business’s 50-day simple moving average is $9.56. The firm has a market cap of $308.03 million, a PE ratio of -2.39 and a beta of 0.47. AMAG Pharmaceuticals has a 52 week low of $7.81 and a 52 week high of $26.10.
In related news, CEO William K. Heiden acquired 10,000 shares of the company’s stock in a transaction dated Thursday, May 9th. The stock was purchased at an average price of $10.70 per share, with a total value of $107,000.00. Following the completion of the purchase, the chief executive officer now owns 490,056 shares in the company, valued at approximately $5,243,599.20. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Elizabeth Scott Bolgiano acquired 5,000 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were bought at an average cost of $10.93 per share, with a total value of $54,650.00. Following the purchase, the insider now owns 74,847 shares of the company’s stock, valued at approximately $818,077.71. The disclosure for this purchase can be found here. Insiders have acquired 328,016 shares of company stock worth $2,904,577 over the last quarter. Company insiders own 4.90% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC purchased a new stake in AMAG Pharmaceuticals during the 2nd quarter valued at $324,000. ClariVest Asset Management LLC grew its position in shares of AMAG Pharmaceuticals by 56.5% in the 1st quarter. ClariVest Asset Management LLC now owns 154,776 shares of the specialty pharmaceutical company’s stock valued at $1,993,000 after acquiring an additional 55,892 shares during the period. Permanens Capital L.P. acquired a new stake in shares of AMAG Pharmaceuticals during the 1st quarter worth about $818,000. NumerixS Investment Technologies Inc lifted its stake in shares of AMAG Pharmaceuticals by 17.8% during the 1st quarter. NumerixS Investment Technologies Inc now owns 7,166 shares of the specialty pharmaceutical company’s stock worth $90,000 after buying an additional 1,083 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its stake in shares of AMAG Pharmaceuticals by 22.2% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 18,150 shares of the specialty pharmaceutical company’s stock worth $445,000 after buying an additional 3,300 shares during the last quarter.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: What is Cost of Goods Sold (COGS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.